Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDec formulation comparison in healthy volunteers
NCT06291285Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of decitabine in sickle cell disease (SCD) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma decitabine concentration-time curve after a single dose at 48 hours. Started Feb 2024; status: completed.
02
Drugs
decitabine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06291285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291285.